Protocol summary
-
Study aim
-
Comparison of the efficacy of Phenytoin and Levetiracetam in children with benzodiazepine-resistant status epilepticus.
-
Design
-
Study Type: Randomized Controlled Trial (RCT).
Randomization: Block randomization using blocks of 2, 4, and 8.
Blinding: Double-blinding is not feasible due to differences in infusion durations.
-
Settings and conduct
-
Location: Mofid Hospital, Tehran.
Procedure: Patients with persistent status epilepticus after two doses of benzodiazepines are randomized into one of the two treatment groups
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria:
Boys or girls aged 6 months to 17 years and 11 months.
Benzodiazepine-resistant status epilepticus (BRSE) after two doses of benzodiazepines.
Exclusion Criteria:
Known or suspected pregnancy.
Allergy or contraindication to Levetiracetam or Phenytoin.
Known renal failure (renal function below 50% of the expected for age).
Prior administration of a second-line antiepileptic drug before emergency department admission.
Seizures following head trauma.
Underlying heart disease.
-
Intervention groups
-
Group 1: Intravenous Levetiracetam at a dose of 40 mg/kg over 5 minutes (maximum dose 2.5 g).
Group 2: Intravenous Phenytoin at a dose of 20 mg/kg over at least 20 minutes (maximum dose 2 g at a maximum infusion rate of 1 mg/kg/min).
-
Main outcome variables
-
Primary Outcome: Time from the start of drug infusion to the cessation of all observable seizure activity.
Secondary Outcomes: Requirement for additional antiepileptic drugs, ICU admission, and occurrence of serious adverse events (death, respiratory depression, cardiovascular instability).
General information
-
Reason for update
-
Dear IRCT Reviewer/Expert,
With due respect, following the progress of our research project and a re-evaluation of the study methodology, we hereby request an adjustment of the sample size from 128 to 78 patients.
This reduction in sample size accounts for project time constraints and operational challenges in enrolling eligible patients (due to strict inclusion and exclusion criteria maintained to uphold scientific rigor), aimed at avoiding unnecessary delays in completing the study. Please note that a post-hoc power analysis was re-calculated, confirming that a sample size of 78 provides adequate statistical power and validity to evaluate the primary outcomes of the study.
Thank you very much in advance for your time, consideration, and assistance.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20241019063425N1
Registration date:
2025-01-02, 1403/10/13
Registration timing:
registered_while_recruiting
Last update:
2026-09-12, 1405/06/21
Update count:
1
-
Registration date
-
2025-01-02, 1403/10/13
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2024-12-30, 1403/10/10
-
Expected recruitment end date
-
2025-12-22, 1404/10/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Comparison of the Efficacy of Phenytoin and Levetiracetam in Children with Benzodiazepine-Resistant Status Epilepticus: A Randomized Controlled Clinical Trial
-
Public title
-
Trial of Phenytoin and Levetiracetam in Children with Resistant Status Epilepticus
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Boys or girls aged 6 months to 17 years and 11 months
The patient has received two consecutive doses of first-line treatment but continues to experience ongoing status epilepticus.
Exclusion criteria:
Patients with known or suspected pregnancy
Patients with a known contraindication or allergy to Levetiracetam or Phenytoin
Patients with known renal failure (patients undergoing hemodialysis or with renal function below 50% of the expected for their age)
Prior administration of a second-line antiepileptic drug before admission to the emergency department
Seizures following head trauma
Individuals with underlying heart disease
-
Age
-
From 6 months old to 18 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
No information
-
Sample size
-
Target sample size:
78
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Double-blinding is not feasible due to the difference in the infusion durations of these two drugs. A random sequence prepared in advance, using blocks of 2, 4, and 8, is generated through simple randomization and used to assign each patient to a treatment. Patients are entered into the random sequence based on the order of their arrival.
-
Blinding (investigator's opinion)
-
Not blinded
-
Blinding description
-
-
Placebo
-
Not used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2024-10-12, 1403/07/21
-
Ethics committee reference number
-
IR.SBMU.MSP.REC.1403.390
Health conditions studied
1
-
Description of health condition studied
-
status epilepticus
-
ICD-10 code
-
G40.301
-
ICD-10 code description
-
refractory status epilepticus
Primary outcomes
1
-
Description
-
The time from the start of drug injection to the cessation of all visible signs of seizure activity, which is defined as the cessation of all rhythmic seizure activity.
-
Timepoint
-
From the time of drug injection to the end of epileptic status
-
Method of measurement
-
using a stopwatch by the therapist
Secondary outcomes
1
-
Description
-
The need for tertiary anticonvulsants to manage seizures after second-line therapy
-
Timepoint
-
After failure to respond to second-line therapy
-
Method of measurement
-
The number of patients who needed third-line treatment is recorded in each group
Intervention groups
1
-
Description
-
Intervention group: Levetiracetam is administered over 5 minutes at a dose of 40 mg/kg, with a maximum dose of 2.5 grams. Following the initiation of injection, the patient is monitored by the resident for the cessation of SE symptoms, and when possible, a video recording is made to document the exact time SE ends. During SE treatment, the APLS algorithm is always followed, and emergency measures (e.g., intubation) are performed if necessary.
-
Category
-
Treatment - Drugs
2
-
Description
-
Intervention group: Phenytoin is administered over a minimum of 20 minutes at a dose of 20 mg/kg, with a maximum dose of 2 grams and an infusion rate of no more than 1 mg/kg/min. If one medication does not result in a response, the patient is reevaluated, and the persistence of SE is confirmed before initiating another medication. For instance, if the patient does not respond to phenytoin, levetiracetam will be started. The response to phenytoin is assessed up to 25 minutes after initiation, while the response to levetiracetam is evaluated up to 10 minutes after the start of infusion. Patients' outcomes are documented accordingly.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Shahid Beheshti University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
No - There is not a plan to make this available
-
Justification/reason for indecision/not sharing IPD
-
There is no further information
-
Study Protocol
-
No - There is not a plan to make this available
-
Statistical Analysis Plan
-
No - There is not a plan to make this available
-
Informed Consent Form
-
No - There is not a plan to make this available
-
Clinical Study Report
-
No - There is not a plan to make this available
-
Analytic Code
-
No - There is not a plan to make this available
-
Data Dictionary
-
No - There is not a plan to make this available